10/725,277a

Connecting via Winsock to STN

Structure search 2/8/05



4 hits but no art

Welcome to STN International! Enter x:x

LOGINID:SSSPTAAJP1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 26	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)

NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:47:58 ON 08 FEB 2005

=> fil reg

=> fil reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:48:06 ON 08 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0
DICTIONARY FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10859476\10725277a.str



chain nodes :
19 20 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
7-20 8-19 17-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
13-16 14-15 14-18 16-17 17-18
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 7-20 8-9 8-19 10-11 10-15 11-12
12-13 13-14 13-16 14-15 14-18 16-17 17-18 17-20

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1
SAMPLE SEARCH INITIATED 15:48:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 213 TO ITERATE

100.0% PROCESSED 213 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3385 TO 5135
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s L1 full
FULL SEARCH INITIATED 15:48:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4098 TO ITERATE

100.0% PROCESSED 4098 ITERATIONS 33 ANSWERS
SEARCH TIME: 00.00.01

L3 33 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 15:48:52 ON 08 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 7 Feb 2005 (20050207/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3
L4 4 L3

=> d L4 ibib abs hitstr 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:2190 CAPLUS
DOCUMENT NUMBER: 142:93676
TITLE: A preparation of sulfonamide substituted indolinones, useful as inhibitors of DNA dependent protein kinase (DNA-PK)
INVENTOR(S): Howlett, Anthony R.; Rice, Audie; Moshinsky, Deborah; Hammarsten, Ola
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004266843	A1	20041230	US 2004-793943		20040308
PRIORITY APPLN. INFO.:			US 2003-452549P	P	20030307

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of sulfonamide substituted indolinones of formula I [wherein: R1 and R2 are independently selected from H, (un)substituted Ph, thiazolyl, or alkyl, etc.; R3, R4, and R5 are independently selected from H or alkyl], useful as inhibitors of DNA dependent protein kinase (DNA-PK). The invention relates to the field of

radiosensitizing agents which are capable of enhancing radiotherapy by inhibiting DNA-PK (DNA-protein kinase). For instance, sulfonamide substituted indolinone II was prepared via condensation of pyrrole derivative III and indole derivative IV. The prepared indolinone derivative V was found to
inhibit DNA-PK (IC50 = 1.6 μM).

IT **775321-71-6P 775321-76-1P 775321-90-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamide substituted indolinones useful as inhibitors of DNA dependent protein kinase (DNA-PK))

RN 775321-71-6 CAPLUS
CN 1H-Indole, 1-[[(3Z)-3-[[3-[3-(dimethylamino)propyl]-4,5,6,7-tetrahydro-6,6-dimethyl-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-76-1 CAPLUS
CN 1H-Indole, 1-[[(3Z)-3-[[3-[3-(diethylamino)propyl]-4,5,6,7-tetrahydro-6,6-dimethyl-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-90-9 CAPLUS
CN 1H-Indole, 1-[[(3Z)-2,3-dihydro-2-oxo-3-[[4,5,6,7-tetrahydro-6,6-dimethyl-3-[3-(4-morpholinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:857170 CAPLUS
DOCUMENT NUMBER: 141:350032
TITLE: Preparation of 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho; Liang, Congxin; Miller, Todd; Lipson, Kenneth E.
PATENT ASSIGNEE(S): Sugen Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 58 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004204407	A1	20041014	US 2004-793952		20040308
PRIORITY APPLN. INFO.:			US 2003-452552P	P	20030307

OTHER SOURCE(S): MARPAT 141:350032
GI

10/793,952



I



II

AB The title compds. [I; R1 and R2 combine to form (un)substituted optionally fused heterocyclic ring; R3-R5 = H, alkyl, hydroxyalkyl, etc.; or R3 and R4 may combine to form a cyclic 6-membered alicyclic ring which may be substituted with one or more lower alkyl] that modulate the activity of protein kinases ("PKs") and are therefore useful in treating disorders related to abnormal PK activity (no biol. data), were prepared General method of synthesis of the compds. I by condensation of oxindoles and aldehydes (preparation of intermediates is given) is described. Eighty-two compds. I (e.g., II) were prepared Pharmaceutical compns. comprising the compds. I, methods of treating diseases utilizing pharmaceutical compns. comprising these compds. and methods of preparing them are also disclosed.

IT **775321-71-6P 775321-76-1P 775321-90-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-sulfonamido-substituted indolinone compds. as protein kinase inhibitors)

RN 775321-71-6 CAPLUS

CN 1H-Indole, 1-[[(3Z)-3-[[3-[3-(dimethylamino)propyl]-4,5,6,7-tetrahydro-6,6-dimethyl-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



no hydro not in our app

RN 775321-76-1 CAPLUS

CN 1H-Indole, 1-[[(3Z)-3-[[3-[3-(diethylamino)propyl]-4,5,6,7-tetrahydro-6,6-dimethyl-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



no hydro not in our app

RN 775321-90-9 CAPLUS
CN 1H-Indole, 1-[[(3Z)-2,3-dihydro-2-oxo-3-[[4,5,6,7-tetrahydro-6,6-dimethyl-3-[3-(4-morpholinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



10 - dihydro not in our app

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:539677 CAPLUS
DOCUMENT NUMBER: 137:109202
TITLE: Preparation of 4-aryl substituted indolinones as protein kinase signal transduction modulators for inhibiting abnormal cell proliferation
INVENTOR(S): Cui, Jingrong; Zhang, Ruofei; Shen, Hong; Chu, Ji Yu; Zhang, Fang-Jie; Koenig, Marcel; Do, Steven Huy; Li, Xiaoyuan; Wei, Chung Chen; Tang, Peng Cho
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 560 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055517	A2	20020718	WO 2001-US48564	20011220
WO 2002055517	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432114	AA	20020718	CA 2001-2432114	20011220
US 2003069297	A1	20030410	US 2001-23488	20011220
US 6677368	B2	20040113		
EP 1349852	A2	20031008	EP 2001-997065	20011220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004518669	T2	20040624	JP 2002-556186	20011220
US 2004157909	A1	20040812	US 2003-736243	20031216
PRIORITY APPLN. INFO.:			US 2000-256479P	P 20001220
			US 2001-23488	A3 20011220

WO 2001-US48564 W 20011220

OTHER SOURCE(S): MARPAT 137:109202
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = (un)substituted aryl or heteroaryl; R2 = H, halo, alkyl, alkenyl, alkynyl, heterocyclyl, etc.; R3 = (un)substituted pyrrole or cycloalkenylpyrrole], as well as pharmaceutical compns. thereof, are prepared and disclosed as compds. capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Thus II, was prepared via condensation of 4-phenyl-1,3-dihydroindol-2-one with 5-formyl-2-methyl-4-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxylic acid Et ester. I were evaluated against eight specfic kinases, e.g., FGFR1, for which I possessed IC50 values (μM) of 0.0091-2.07. The present invention also relates to methods for treating protein kinase related disorders.

IT **442559-47-9P 442559-48-0P 442559-49-1P**
442559-50-4P 442559-51-5P 442559-52-6P
442562-17-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of (aryl)(pyrrolylmethylene)indolinones as protein kinase signal transduction modulators)

RN 442559-47-9 CAPLUS

CN 2H-Indol-2-one, 4-(2-fluorophenyl)-1,3-dihydro-3-[[4,5,6,7-tetrahydro-5-[2-(1-pyrrolidinyl)ethyl]-1H-indol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



tetrahydro

close but
our app = benzene
not tetrahydro

RN 442559-48-0 CAPLUS

CN 2H-Indol-2-one, 4-(3-fluorophenyl)-1,3-dihydro-3-[[4,5,6,7-tetrahydro-5-[2-(1-pyrrolidinyl)ethyl]-1H-indol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442559-49-1 CAPLUS
CN 2H-Indol-2-one, 4-(2-fluorophenyl)-1,3-dihydro-3-[[4,5,6,7-tetrahydro-5-[2-(4-morpholinyl)ethyl]-1H-indol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442559-50-4 CAPLUS
CN 2H-Indol-2-one, 4-(3-fluorophenyl)-1,3-dihydro-3-[[4,5,6,7-tetrahydro-5-[2-(4-morpholinyl)ethyl]-1H-indol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442559-51-5 CAPLUS

CN 2H-Indol-2-one, 4-(2-fluorophenyl)-1,3-dihydro-3-[[4,5,6,7-tetrahydro-5-[2-(4-methyl-1-piperazinyl)ethyl]-1H-indol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442559-52-6 CAPLUS
CN 2H-Indol-2-one, 4-(3-fluorophenyl)-1,3-dihydro-3-[[4,5,6,7-tetrahydro-5-[2-(4-methyl-1-piperazinyl)ethyl]-1H-indol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442562-17-6 CAPLUS
CN 2H-Indol-2-one, 4-(3-fluorophenyl)-1,3-dihydro-3-[[4,5,6,7-tetrahydro-4-[2-(1-pyrrolidinyl)ethyl]-1H-indol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



not art

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:904107 CAPLUS
DOCUMENT NUMBER: 136:37505
TITLE: Preparation of 3-(2-indolylmethylene)-2-indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases
INVENTOR(S): Tang, Peng Cho; Harris, G. Davis; Li, Xiaoyuan
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

our app

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094312	A2	20011213	WO 2001-US17961	20010604
WO 2001094312	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2410509	AA	20011213	CA 2001-2410509	20010604
US 2002052369	A1	20020502	US 2001-871700	20010604
US 6706709	B2	20040316		
EP 1294688	A2	20030326	EP 2001-946059	20010604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003535847	T2	20031202	JP 2002-501862	20010604
US 2004147586	A1	20040729	US 2003-725277	20031202

PRIORITY APPLN. INFO.:	US 2000-209162P	P	20000602
	US 2001-871700	A3	20010604
	WO 2001-US17961	W	20010604

OTHER SOURCE(S): MARPAT 136:37505

GI



I



II

AB Title compds. I [wherein R4-R6 and R8-R10 = H; R1, R2, and R3 = independently H, halo, carboxylic acid, trihalomethyl, or (un)substituted ester, amide, alkyl, alkoxy, or (hetero)aryl; R7 = (un)substituted alkyl or alkoxy; or pharmaceutically acceptable salt thereof] were prepared as modulators of the activity of protein kinases (PKs) and phosphatases. For example, 5-bromo-2-oxindole was coupled with 5-(3-diethylaminopropyl)-1H-indole-2-carbaldehyde (preparation given) in the presence of piperidine in EtOH to afford II, which inhibited GST-FLK-1, EGF receptor kinase, and PDGF with IC50 values of 0.03 μM, 2.87 μM, and 0.38 μM, resp. I are useful in treating disorders related to abnormal PK activity, such as blood vessel proliferative disorders, mesangial cell proliferative disorders, fibrotic disorders, cancer, diabetes, autoimmune disorders, hyperproliferation disorders, restenosis, fibrosis, psoriasis, von Heppel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, inflammatory disorders, immunol. disorders, and cardiovascular disorders (no data). Combinatorial libraries comprising at least five indolinone compds., formed by reacting oxindoles with aldehydes, are also claimed.

IT **380241-33-8P**
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)

RN 380241-33-8 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



IT **380242-44-4P 380242-45-5P 380242-46-6P**
380242-47-7P 380242-48-8P 380242-49-9P
380242-50-2P 380242-51-3P 380242-52-4P
380242-53-5P 380242-67-1P 380242-68-2P
380242-69-3P 380242-70-6P 380242-71-7P
380242-72-8P 380242-73-9P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)

RN 380242-44-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-45-5 CAPLUS
CN Piperazine, 1-[[3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 380242-46-6 CAPLUS
CN Pyrrolidine, 1-[[3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 380242-47-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-(2-methoxyethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-48-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 380242-49-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-(2-methoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-50-2 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-51-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-N-[(4-fluorophenyl)methyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-52-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-53-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-67-1 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380242-68-2 CAPLUS
CN Glycine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 380242-69-3 CAPLUS
CN Glycine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 380242-70-6 CAPLUS
CN L-Alanine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 380242-71-7 CAPLUS
CN L-Valine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 380242-72-8 CAPLUS
CN L-Alanine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 380242-73-9 CAPLUS
CN L-Valine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-

2-yl]methylene]-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT **380241-13-4P 380241-14-5P 380241-15-6P 380241-16-7P 380241-32-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)

RN 380241-13-4 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-14-5 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-15-6 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)



RN 380241-16-7 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro-5-phenyl- (9CI) (CA INDEX NAME)



RN 380241-32-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.66	182.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.92	-2.92

STN INTERNATIONAL LOGOFF AT 15:50:19 ON 08 FEB 2005